نتایج جستجو برای: peginterferon

تعداد نتایج: 9316  

2013
Zongguo Yang Liping Zhuang Lei Yang Xiaorong Chen

Background. The efficacy and tolerability of peginterferon α -2a and peginterferon α -2b in chronic hepatitis C (CHC) patients remain controversial. Methods. PubMed, Ovid, and Cochrane libraries were electronically searched until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently. Results. The overall sustained virologic respons...

Journal: :The New England journal of medicine 2009
John G McHutchison Eric J Lawitz Mitchell L Shiffman Andrew J Muir Greg W Galler Jonathan McCone Lisa M Nyberg William M Lee Reem H Ghalib Eugene R Schiff Joseph S Galati Bruce R Bacon Mitchell N Davis Pabak Mukhopadhyay Kenneth Koury Stephanie Noviello Lisa D Pedicone Clifford A Brass Janice K Albrecht Mark S Sulkowski

BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. METHODS At 118 sites, patients who had HCV genotype 1 infection and who had not previously been treated were randomly assigned to undergo 48 weeks of treatment...

Journal: :Antiviral therapy 2005
Raffaele Bruno Paolo Sacchi Laura Maiocchi Cristina Zocchetti Valentina Ciappina Savino Patruno Gaetano Filice

One reason for dosing a drug by body weight is to reduce interpatient variability in clinical response. This study evaluated the relationship between body weight and drug exposure for peginterferon alpha-2a and peginterferon alpha-2b used in combination with ribavirin for treating patients with chronic hepatitis C. These two products are dosed differently: peginterferon alpha-2a is flat-dosed a...

Journal: :Journal of infection in developing countries 2016
Yingfeng An Shoucui Gao Daxin Cheng Xiaojing Wang Liang Bai Enqi Liu Yonglie Chu Sihai Zhao

INTRODUCTION Traditional Chinese herbs are widely used for the treatment of chronic hepatitis B (CHB) in China. The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) comparing peginterferon therapies with peginterferon plus Chinese herbal therapies in hepatitis B e antigen (HBeAg)-positive CHB patients. METHODOLOGY The main biomedical databases were searc...

2012
Eric Druyts Edward J Mills Jean Nachega Christopher O’Regan Curtis L Cooper

BACKGROUND With the development of new direct acting antiviral (DAA) therapy for hepatitis C, the backbone peginterferon alpha used may be of importance in maximizing treatment outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment discontinuation among hepatitis C genotype 1-infected patients given peginterferon alpha-2a plus ribavirin or peginterferon a...

Journal: :Annals of hepatology 2009
Billur Canbakan Hakan Akin Gulgun Tahan Orhan Tarcin Fatih Eren Ozlen Atug Veysel Tahan Nese Imeryuz Ozlem Yapicier Erol Avsar Nurdan Tozun

OBJECTIVE To test the effects of peginterferon in an unrecoverable model of bile-duct ligation (BDL) induced liver fibrosis. MATERIAL AND METHODS Thirty-seven Wistar rats were divided into five groups: group 1, BDL + peginterferon (n = 8); group 2, BDL (n = 8); group 3, sham + peginterferon (n = 7); group 4, sham (n = 7); and group 5, control group (n = 7). Peginterferon-alpha 2b (50 microgr/...

2013
Masato Nakamura Tatsuo Kanda Tatsuo Miyamura Shuang Wu Shingo Nakamoto Osamu Yokosuka

Alanine aminotransferase (ALT) elevation was occassionally observed during the treatment with combination peginterferon alpha plus ribavirin. Two forms of peginterferon are currently available as a standard of care with or without direct-acting antivirals against hepatitis C virus (HCV). Until the appearance of interferon-sparing regimen, peginterferon alpha plus ribavirin will play a central r...

Journal: :hepatitis monthly 0
mahdiyar pouresmaeeli baqiyatallah research center for gastroenterology and liver diseases, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran seyed moayed alavian baqiyatallah research center for gastroenterology and liver diseases, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran; baqiyatallah research center for gastroenterology and liver diseases, p. o. box: 14155-3651, tehran, ir iran. tel/fax: +98-2181262072 maryam keshvari blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran shima salimi baqiyatallah research center for gastroenterology and liver diseases, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran leila mehrnoush baqiyatallah research center for gastroenterology and liver diseases, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran

conclusions there was no significant difference in the efficacy of peginterferon-alpha-2a and peginterferon-alpha-2b in iranian patients. physicians might choose the treatment regimen for every individual concerning the differences in side effects of peginterferons. background nearly 0.5% of iranians are infected with hcv. peginterferon-alpha-2a and peginterferon-alpha-2b are the two available ...

Journal: :Annals of hepatology 2003
Francisco Bosques-Padilla Rafael Trejo-Estrada Octaivio Campollo-Rivas Carlos Cortez-Hernández Margarita Dehesa-Violante Héctor Maldonado-Garza Rául Pérez-Gómez Armando Cabrera-Valdespino

Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in ...

Journal: :Archives of medical research 2006
Fernando García-Contreras Armando Nevárez-Sida Patricia Constantino-Casas Fernando Abud-Bastida Juan Garduño-Espinosa

BACKGROUND More than one million individuals in Mexico are infected with hepatitis C virus (HCV), and 80% are at risk for developing a chronic infection that could lead to hepatic cirrhosis and other complications that impact quality of life and institutional costs. The objective of the study was to determine the most cost-effective treatment against HCV among the following: peginterferon, pegi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید